Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Melanoma and other skin tumours

LBA39 - Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study

Date

20 Sep 2021

Session

Mini oral session - Melanoma and other skin tumours

Topics

Clinical Research;  Targeted Therapy;  Immunotherapy

Tumour Site

Melanoma

Presenters

Christian Blank

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

C.U. Blank1, I.L.M. Reijers1, J.M. Versluis1, A.M. Menzies2, P. Dimitriadis3, M.W. Wouters4, R.P.M. Saw5, W.M.C. Klop6, T.E. Pennington2, L.J.W. Bosch7, S. Cornelissen8, L.G. Grijpink-Ongering9, M.J.C. Gregorio10, M. Lopez-Yurda9, R.V. Rawson11, A.J. Spillane2, B.A. van de Wiel12, R.A. Scolyer11, A.C.J. van Akkooi13, G.V. Long14

Author affiliations

  • 1 Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), 1066CX - Amsterdam/NL
  • 2 Medical Oncology Department, Melanoma Institute Australia, 2065 - Wollstonecraft/AU
  • 3 Molecular Oncology And Immunology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), 1066CX - Amsterdam/NL
  • 4 Surgical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), 1066CX - Amsterdam/NL
  • 5 Surgical Oncology Dept, Melanoma Institute Australia, 2065 - Wollstonecraft/AU
  • 6 Surgical Oncology Dept, Netherlands Cancer Institute, 1006 BE - amsterdam/NL
  • 7 Molecular Diagnostics Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), 1066CX - Amsterdam/NL
  • 8 Core Facility Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), 1066CX - Amsterdam/NL
  • 9 Biometrics Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), 1066CX - Amsterdam/NL
  • 10 Clinical Trials Department, Melanoma Institute Australia, 2065 - Wollstonecraft/AU
  • 11 Pathology Department, Royal Prince Alfred Hospital, 2050 - Camperdown/AU
  • 12 Pathology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), 1066 CX - Amsterdam/NL
  • 13 Surgical Oncology Dept, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 14 Medical Oncology Dept, Melanoma Institute Australia, 2065 - Wollstonecraft/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract LBA39

Background

Neoadjuvant (neoadj) IPI + NIVO induces high pathologic response rates (pRR 72-78%) in stage IIIB-D melanoma which is strongly associated with long-term relapse-free survival (RFS). Pts with a low baseline IFN-γ sign are less likely to respond. The class I histone deacetylase inhibitor domatinostat (DOM) increased intratumoral T cell infiltration and IFN-γ sign expression in melanoma. DONIMI tests neoadj combinations of NIVO ± IPI with DOM stratified according to IFN-γ sign from tumor biopsies.

Methods

This phase 1b study tested the safety/feasibility of neoadj NIVO ± DOM ± IPI in stage III RECISTv1.1 measurable melanoma. It also prospectively tested the IFN-γ sign for the first time, randomizing IFN-γ sign high pts to arm A (2 cycles NIVO 240mg q3w) or arm B (2 cycles NIVO 240mg + DOM 200mg BID, d1-14, q3w), and IFN-γ sign low pts to arm C (same treatment regimen as arm B) or arm D (2 cycles NIVO 240mg + IPI 80mg + DOM 200mg QD, d1-14, q3w). Surgery was planned after 6 wks. Adjuvant NIVO 480mg q4w or dabrafenib + trametinib (non-responding BRAFV600 mutated pts) started at week 12 for 52 wks.

Results

Between Jan 2020 - Apr 2021, 40 pts were enrolled (10 pts in each arm). Baseline characteristics were comparable. All treatment regimens were feasible as surgery was performed on time in all pts (wk 6 ± 1 wk). Gr 3-4 systemic treatment-related AEs (trAEs) during the first 12 wks occurred in 0% in arm A, 20% in arm B, 40% in arm C and 20% in arm D. Except for gr 2-3 DOM-related rash, no unexpected trAEs were observed. pRR was 90% in arm A, 80% in arm B (both IFN-γ sign high pts), 30% in arm C and 40% in arm D (both IFN-γ sign low pts). 2 pts in arm D developed distant metastases before surgery. At data cutoff (Jul 7, median FU 8.9 months), estimated 6-month RFS rate was 100% in IFN-γ sign high pts and 79.4% in IFN-γ sign low pts.

Conclusions

Neoadj NIVO ± DOM ± IPI appears safe and feasible. DONIMI shows prospectively the discriminative ability of the IFN-γ sign algorithm. It adequately identified pts who can benefit from NIVO ± DOM alone (IFN-γ high pts) vs pts who might need an alternative scheme (IFN-γ low pts). Standard DOM dosing (200mg BID d1-14) plus IPI + NIVO is currently being tested.

Clinical trial identification

NCT04133948.

Editorial acknowledgement

Legal entity responsible for the study

Netherlands Cancer Institute (PI: Christian Blank).

Funding

4SC.

Disclosure

C.U. Blank: Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: GSK; Financial Interests, Institutional, Advisory Board: AstraZenica; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Advisory Board: Lilly; Financial Interests, Institutional, Advisory Board: Genmab; Financial Interests, Institutional, Advisory Board: Pierre Fabre; Financial Interests, Personal, Advisory Board: Third Rock Ventures; Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Nanostring; Financial Interests, Institutional, Research Grant: 4SC; Financial Interests, Personal, Ownership Interest: Immagene BV. A.M. Menzies: Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Advisory Board: Pierre-Fabre; Financial Interests, Institutional, Advisory Board: QBiotics. R.P.M. Saw: Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: QBiotics; Financial Interests, Institutional, Invited Speaker: BMS; Financial Interests, Institutional, Invited Speaker: Novartis. A.J. Spillane: Non-Financial Interests, Institutional, Advisory Board: QBiotics; Financial Interests, Personal, Other, fees for professional services: Stryker. B.A. van de Wiel: Non-Financial Interests, Institutional, Advisory Board: BMS. R.A. Scolyer: Financial Interests, Institutional, Other, professional services: QBiotics; Financial Interests, Institutional, Other, professional services: Novartis; Financial Interests, Institutional, Other, professional services: MSD; Financial Interests, Institutional, Other, professional services: NeraCare; Financial Interests, Institutional, Other, professional services: Amgen Inc; Financial Interests, Institutional, Other, professional services: BMS; Financial Interests, Institutional, Other, professional services: Myriad Genetics; Financial Interests, Institutional, Other, professional services: GSK. A.C.J. van Akkooi: Financial Interests, Institutional, Advisory Board: Amgen; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Advisory Board: Novartis; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: Merck-Pfizer; Financial Interests, Institutional, Advisory Board: Sanofi; Financial Interests, Institutional, Advisory Board: Sirius Medical; Financial Interests, Institutional, Advisory Board: 4SC; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Research Grant: Merck-Pfizer. G.V. Long: Financial Interests, Institutional, Advisory Board: Aduro Biotech Inc; Financial Interests, Institutional, Advisory Board: Amgen Inc; Financial Interests, Institutional, Advisory Board: Array Biopharma Inc; Financial Interests, Institutional, Advisory Board: Boehringer Ingelheim International GmbH; Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Advisory Board: Highlight Therapeutics S.L.; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Institutional, Advisory Board: Novartis Pharma AG; Financial Interests, Institutional, Advisory Board: Pierre-Fabre; Financial Interests, Institutional, Advisory Board: QBiotics Group Limited; Financial Interests, Institutional, Advisory Board: Regeneron Pharmaceuticals Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.